JCR Pharmaceuticals Co.,Ltd. [4552.T]

TOKYO, May 11 (Pulse News Wire) – JCR Pharmaceuticals Co.,Ltd. (4552) has revised its FY2026/3 Full-Year consolidated earnings forecast. FORECAST REVISION SUMMARY: (Unit: ) Revenue Op Profit Ord Profit Net Profit Previous Forecast (A) 39,500 400 400 1,600 Revised Forecast (B) 40,300 500 1,100 2,100 Change (B-A) 800 100 700 500 Change (%): Revenue +2.0% | OP +25.0% | OrdP +175.0% | NP +31.3% KEY CHANGES: - Revenue forecast raised by +2.0% to 40,300 - Net profit forecast raised by +31.3% to 2,100 - Operating profit forecast raised by +25.0% to 500 REASON FOR REVISION: 8 403 1 7 11 521

Forecast revision — FY2026/3Upward revision

MetricPriorRevisedChange
Revenue¥39,500M¥40,300M+2.0%
Op. profit¥400M¥500M+17.0%
Net profit¥1,600M¥2,100M+3.0%

Source: TDNet filing · Figures in millions of yen

Original Disclosure (PDF)

🟢 Confidence: High AI-translated content.